Gastrointestinal Imaging

Which Imaging Study Is Best for Metastatic Assessment in Squamous Cell Anal Cancer?

·
Which Imaging Study Is Best for Metastatic Assessment in Squamous Cell Anal Cancer?

An oncologist is reviewing the chart of a 64-year-old patient with a new, biopsy-proven diagnosis of T2 squamous cell carcinoma of the anal canal. The local disease will be managed with chemoradiation, but a critical question remains before finalizing the treatment plan: has the cancer spread? The physician needs to order the right imaging study to confidently assess for distant metastatic disease in the lymph nodes, liver, lungs, and beyond. This article provides a focused workflow for this exact clinical decision, explaining why the American College of Radiology (ACR) finds CT of the abdomen and pelvis with IV contrast to be Usually Appropriate for this scenario.

Who Fits This Clinical Scenario for Anal Cancer Metastatic Assessment?

This guidance applies to a specific patient population: adults with a confirmed diagnosis of squamous cell anal cancer who require an assessment for distant metastatic disease. This includes two key moments in the patient journey:

1. Initial Staging: The patient has a new diagnosis, and the care team needs to determine the full extent of the disease (the “M” in TNM staging) before initiating therapy.
2. Surveillance: The patient has completed treatment and is undergoing routine follow-up imaging to monitor for distant recurrence.

It is crucial to distinguish this scenario from similar, but distinct, clinical questions. This workflow does not apply to:

  • Locoregional Staging of the Primary Tumor: If the primary goal is to evaluate the local extent of the anal tumor itself—its size, depth of invasion, and relationship to adjacent structures like the sphincter complex—a different imaging approach is needed. That workup is covered in the ACR variant for locoregional assessment, which often prioritizes pelvic MRI for its superior soft-tissue resolution.
  • Posttreatment Locoregional Assessment: Evaluating the response of the primary tumor and local lymph nodes immediately after chemoradiation is a separate clinical question with its own imaging recommendations.
  • Non-Squamous Histologies: Anal cancers can arise from other cell types, such as adenocarcinoma or melanoma. These have different patterns of spread and may require different imaging strategies. This article is specific to squamous cell carcinoma, the most common type.

What Diagnoses Are You Working Up When Assessing for Metastatic Anal Cancer?

While the primary diagnosis is known, the staging scan is performed to search for evidence of spread to specific locations. The imaging workup is designed to identify or rule out the most common sites of distant disease for squamous cell anal cancer.

Metastatic Nodal Disease: This is the most common pathway of spread. The scan meticulously evaluates key lymph node basins beyond the immediate perirectal region. This includes the inguinal nodes (a common site of drainage for distal anal canal tumors), pelvic nodes (internal iliac, obturator), and higher-echelon nodes like the para-aortic chain. Enlarged or necrotic-appearing nodes are highly suspicious.

Hepatic Metastases: The liver is the most frequent site of hematogenous (blood-borne) spread from anal cancer. The imaging study must be sensitive enough to detect focal liver lesions, which can appear as hypo-enhancing masses on contrast-enhanced CT.

Pulmonary Metastases: The lungs are another primary target for distant spread. The workup must include an evaluation of the lung parenchyma for nodules or masses that would signify metastatic disease and drastically alter the patient’s prognosis and treatment plan.

Bony Metastases: While less common than liver or lung involvement, skeletal metastases can occur. These are consequential findings that may necessitate palliative radiation for pain control. Staging scans can reveal lytic or blastic lesions suspicious for cancer deposits.

Why Is CT of the Abdomen and Pelvis with IV Contrast Usually Appropriate for Metastatic Assessment?

The ACR designates CT of the abdomen and pelvis with IV contrast as Usually Appropriate for assessing metastatic disease in anal cancer because it provides a rapid, widely available, and highly effective survey of the most common sites of spread.

The rationale is rooted in the modality’s strengths for this specific task. CT offers excellent spatial resolution to identify even small, sub-centimeter lymph nodes and characterize their morphology. The administration of intravenous contrast is critical; it enhances the solid abdominal organs, making liver metastases more conspicuous against the background parenchyma. It also opacifies blood vessels and helps delineate lymph nodes from adjacent vascular structures.

For a complete metastatic workup, this study is almost always performed in conjunction with a CT of the chest. The ACR separately rates both CT chest with IV contrast and CT chest without IV contrast as Usually Appropriate. Combining these into a single CT chest/abdomen/pelvis examination provides a comprehensive one-stop assessment of the most common sites of distant disease (lungs, liver, lymph nodes, and bone). The total radiation dose for a combined study is moderate, typically in the ☢☢☢☢ 10-30 mSv range.

How do alternative studies compare?

  • FDG-PET/CT skull base to mid-thigh: This is also rated Usually Appropriate and is an excellent staging tool. It combines anatomic detail from CT with functional information about metabolic activity, potentially identifying small or unexpected metastases missed by CT alone. However, it carries a higher radiation dose (☢☢☢☢ 10-30 mSv) and is a more resource-intensive study. It is often reserved for patients with high-risk disease, for clarifying equivocal findings on a conventional CT, or as part of radiation therapy planning.
  • MRI abdomen and pelvis without and with IV contrast: Rated as May be appropriate, this study is a powerful problem-solver but is not the recommended first-line screening tool for metastases. It provides exceptional characterization of indeterminate liver lesions without using ionizing radiation (O 0 mSv). However, it is more time-consuming, susceptible to motion artifact, and does not evaluate the chest, requiring a separate study for a complete workup.

Once you’ve decided on CT for staging, our protocol guide covers the technique, contrast, and reading principles: CT Chest/Abdomen/Pelvis with IV Contrast.

What Is the Downstream Workflow After a Staging CT for Anal Cancer?

The results of the staging CT directly influence the patient’s prognosis and treatment plan, creating clear next steps in the clinical workflow.

  • If the study is negative for distant metastases: The patient is considered to have non-metastatic (Stage I-III) disease. The focus remains on curative-intent local therapy, typically definitive chemoradiation. The baseline scan also serves as a valuable point of comparison for future surveillance imaging.
  • If the study is positive for distant metastases: The patient is upstaged to Stage IV. This fundamentally changes the goal of treatment from curative to palliative. The therapeutic approach shifts to systemic chemotherapy to control disease, prolong survival, and manage symptoms. Biopsy of a metastatic site may be considered to confirm the diagnosis if there is any ambiguity.
  • If the study is indeterminate: An equivocal finding, such as a small, non-specific liver lesion or a borderline-sized lymph node, requires further investigation. The next step is often a more specific imaging study. For an indeterminate liver lesion, an MRI of the abdomen and pelvis with and without IV contrast (May be appropriate) is the ideal follow-up test due to its superior tissue characterization. For an accessible suspicious lymph node, an image-guided or excisional biopsy may be necessary.

Pitfalls to Avoid (and When to Get Help)

When ordering and interpreting imaging for metastatic anal cancer, be mindful of these common pitfalls:

  • Omitting the Chest: Staging for distant disease is incomplete without evaluating the lungs. Always order a CT of the chest in addition to the abdomen and pelvis.
  • Forgetting IV Contrast: A non-contrast CT of the abdomen and pelvis (May be appropriate) has significantly lower sensitivity for detecting liver metastases and characterizing lymph nodes. Unless there is a strong contraindication (e.g., severe allergy, renal failure), IV contrast is essential.
  • Misinterpreting Reactive Nodes: Inguinal lymph nodes can be enlarged due to reactive changes from the primary tumor or infection, not just metastasis. Nodal size criteria are not absolute; features like central necrosis are more specific for malignancy.
  • Ignoring Surveillance Timing: For post-treatment surveillance, follow established guidelines (e.g., NCCN) for the timing and frequency of scans to avoid unnecessary radiation exposure while still detecting recurrences in a timely manner.

If imaging findings are complex or equivocal, discussion at a multidisciplinary tumor board with input from radiology, medical oncology, radiation oncology, and surgery is the standard of care.

Related ACR Topics and Tools

This article focuses on a single clinical scenario. For a comprehensive overview of all imaging decisions in this domain, or to explore the technical details of the recommended studies, the following resources are available.

Frequently Asked Questions

Why is CT preferred over PET/CT for initial metastatic assessment in all cases?

CT is not always preferred, but it is a highly appropriate and more accessible first step. Both CT and FDG-PET/CT are rated ‘Usually Appropriate’ by the ACR. CT is faster, less expensive, and involves a lower radiation dose. PET/CT provides additional functional information and may be more sensitive for small or unexpected sites of disease. Many institutions reserve PET/CT for patients with high-risk features (e.g., large primary tumors, bulky nodal disease) or to clarify ambiguous findings on an initial CT scan.

If my patient has an allergy to iodinated contrast, what is the best alternative?

If a patient has a severe contrast allergy, a non-contrast CT of the chest, abdomen, and pelvis can be performed. However, its sensitivity for liver metastases is reduced. An alternative strategy is to perform a non-contrast chest CT and an MRI of the abdomen and pelvis with and without a gadolinium-based contrast agent (assuming no contraindication to gadolinium). FDG-PET/CT is also an excellent alternative as the CT portion can be performed without IV contrast while still providing valuable functional information.

Is a CT scan necessary if the patient is undergoing surveillance with no symptoms?

Yes, routine surveillance imaging is a standard part of post-treatment follow-up for anal cancer, even in asymptomatic patients. The goal is to detect recurrent disease at an early, potentially treatable stage. The frequency and duration of surveillance imaging are guided by protocols from organizations like the National Comprehensive Cancer Network (NCCN).

How does this imaging recommendation change if the patient has adenocarcinoma of the anus instead of squamous cell carcinoma?

This ACR guidance is specific to squamous cell carcinoma. While the initial imaging workup for adenocarcinoma may be similar (CT chest/abdomen/pelvis), the patterns of spread and response to therapy can differ. Adenocarcinoma of the anal canal is often managed similarly to rectal adenocarcinoma, which has its own distinct and detailed staging and surveillance guidelines. It is crucial to apply the correct histology-specific guidelines.

What is the role of MRI for the primary purpose of assessing for distant metastases?

For the initial, comprehensive screen for distant metastases, MRI is not the primary tool. It is rated ‘May be appropriate’. Its main role in this context is as a problem-solving modality, particularly for characterizing an indeterminate liver lesion found on CT. While whole-body MRI protocols exist for metastatic screening, they are not as widely available or standardized as CT and are not the first-line recommendation in this scenario.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026